DOSEGUY

Empagliflozin

most data

Also seen as: Jardiance, BI 10773, BI-10773, empa

The Dose Guy’s verdict
Sep 1, 2026
5 sources

If your blood sugar, blood pressure, or kidney function is flagged, empagliflozin earns its place. Real cardiovascular and kidney outcome data on tens of thousands of patients, not projections: fewer deaths, fewer hospitalizations, slower kidney decline. The catch is that nearly all of those patients had diabetes, heart failure, or kidney disease. If your metabolic panel is clean and you are chasing a longevity benefit, you are running ahead of the evidence.

Would I take it?Yes, if the panel says so.

What it is

An SGLT2 inhibitor. It blocks glucose reabsorption in the kidney, so your body dumps sugar through the urine instead of recycling it. The blood-sugar drop is the obvious part. The less obvious part, and the reason the longevity crowd noticed, is what happens downstream: lower fluid volume, lower blood pressure, less cardiac workload, and a kidney-protective effect that the glucose story alone does not explain. The trials kept winning in populations without diabetes, which is what moved empagliflozin from a diabetes drug to something broader.

Among the SGLT2 inhibitors, empagliflozin and dapagliflozin carry the deepest outcome data. If your doctor prescribes either, you are covered. The relevant question is whether you have a reason to run one at all, and that reason should come from your bloodwork, not from a longevity podcast.

What the research shows

The evidence base is unusually deep for a compound this audience reaches for:

In drug-naive type 2 diabetes at 24 weeks, empagliflozin 10 mg reduced HbA1c by 0.74 percentage points versus placebo, and 25 mg reduced it by 0.85 points.Lancet DE 2014 · phase 3 · n=899
In type 2 diabetes with high cardiovascular risk, empagliflozin reduced cardiovascular death by 38% and all-cause death by 32% over a median 3.1 years.NEJM 2015 · EMPA-REG · n=7020
In heart failure with reduced ejection fraction, cardiovascular death or heart-failure hospitalization dropped from 24.7% to 19.4%, with consistent benefit whether or not the patient had diabetes.NEJM 2020 · EMPEROR-Reduced · n=3730
In chronic kidney disease with or without diabetes, kidney-disease progression or cardiovascular death fell from 16.9% to 13.1% over a median 2 years.NEJM 2022 · EMPA-KIDNEY · n=6609
After acute myocardial infarction, first heart-failure hospitalization or all-cause death occurred in 8.2% with empagliflozin and 9.1% with placebo, hazard ratio 0.90, p=0.21. The trial missed its primary endpoint.NEJM 2024 · EMPACT-MI · n=6522

Realistic protocols

10 mg once daily, any time, with or without food. Most people stay at 10 mg. The 25 mg dose exists. In the monotherapy trial it reduced HbA1c by 0.85 percentage points versus 0.74 at 10 mg, a marginal gain. The cardiovascular and kidney benefits showed up at 10 mg, and the outcome trials did not separate the two doses.

Drink more water than you think you need. Empagliflozin makes you urinate more, and the glucose in the urine creates an environment yeast love. Genital hygiene matters: keep the area dry and clean, and treat any itch early before it becomes a real infection. If you are stacking other blood-pressure tools like HCTZ or eplerenone, watch for volume depletion, especially in the first few weeks.

The glycosuria does burn some extra calories. That is real but modest, a side effect, not a weight-loss strategy.

Standard10 mg/dayOnce daily, any time. The dose nearly everyone runs.
Ceiling25 mg/dayMarginal extra glucose lowering. Outcome trials did not separate the two.
Hydrationextra waterYou will urinate more. Replace what you lose.

Side effects

The side profile is clean relative to the benefits, but the class has a few signatures:

commonGenital yeast infections, especially in women. The glucose in the urine feeds the yeast. Good hygiene and early treatment keep it manageable.
commonIncreased urination and mild volume depletion, worst in the first couple weeks and when stacking other diuretics.
monitorAn initial eGFR dip in the first two months. This reverses and the long-term slope is better, but it can look alarming on a lab panel if you are not expecting it.
monitorEuglycemic diabetic ketoacidosis, rare but real, and easy to miss because blood sugar stays normal. Risk goes up with fasting, dehydration, or very low carb. If you feel unusually sick with nausea and deep breathing, check ketones.

Where to buy

PCT.zone–
$10.55 / 25mg vial$0.42/mg
✓ verified Sep 12
Read review →
Visit →

Prices move. Links are affiliate links; they never change a ranking, and scores are set before the deal exists.